15 research outputs found
CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
Get PDFCD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx
Quantitative Characterization of E-selectin Interaction with Native CD44 and P-selectin Glycoprotein Ligand-1 (PSGL-1) Using a Real Time Immunoprecipitation-based Binding Assay
No full textInhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion
No full text10.1007/s00280-008-0684-zCancer Chemotherapy and Pharmacology626949-95
Re-expression of DNA methylation-silenced CD44 gene in a resistant NB4 cell line: rescue of CD44-dependent cell death by cAMP
No full text
The Effect of Anti-CD44 Monoclonal Antibodies on Differentiation and Proliferation of Human Acute Myeloid Leukemia Cells
No full text
